background: A concern for new compounds in fertility treatment is the possible risk of perinatal complications or birth defects. To demonstrate long-term safety of ganirelix (GnRH antagonist) treatment in controlled ovarian stimulation (COS), follow-up data on pregnancy and neonatal outcome were analysed for 1000 fetuses (≥16 gestational weeks).
Introduction
A general concern for new procedures or compounds in assisted reproduction techniques (ART) is the possible risk of perinatal complications or birth defects in infants conceived by ART. Routine IVF procedures-using GnRH agonists for the prevention of premature LH rises during treatment with FSH or hMG for controlled ovarian stimulation (COS)-have become accepted as being safe. This was based on the initial reassuring results of most follow-up studies, either prospective or retrospective, indicating that the nature and incidences of obstetrical complications and congenital malformations were similar to those occurring in the general population (Bergh et al., 1999; Westergaard et al., 1999; Tarlatzis and Bili, 2000; Ericson and Kallen, 2001; Anthony et al., 2002) . In these studies a higher perinatal mortality and/or an increased risk of some birth defects (such as hydrocephaly and oesophageal atresia) were observed in the IVF group, but this could be attributed to the higher incidence of multiple pregnancies and to maternal characteristics, rather than to the IVF procedure itself. More recently some meta-analyses suggested that infants, both singletons and multiples, born following ART are at increased risk of perinatal complications (Helmerhorst et al., 2004; Jackson et al., 2004) and birth defects (Rimm et al., 2004; Hansen et al., 2005) compared with spontaneous conceptions. The latest available review on outcome of assisted reproduction (Sutcliffe and Ludwig, 2007) , concludes that some of the risks to infants born following ART do not arise as a result of the applied techniques or treatments but rather result from the underlying health risks of being subfertile, as also suggested by Zhu et al. (2006) . Possible risks, including an increased risk of major malformations (1.3 times incidence in spontaneous conceiving couples), need to be explained to any couple considering ART and patients need to be adequately counselled prior to starting treatment.
Since 2000, the GnRH antagonist ganirelix (Orgalutran w ; N.V. Organon, Oss, The Netherlands) has been used for the prevention of premature LH surges in COS for IVF/ICSI. Ganirelix is a synthetic decapeptide that possesses high antagonistic activity to GnRH, and reversibly inhibits the secretion of pituitary gonadotrophins. Application of a GnRH antagonist protocol in COS has the advantage of a shorter treatment duration, and is considered to improve patient convenience and compliance. To investigate the long-term safety of ganirelix treatment for IVF or ICSI, follow-up data of a phase two dose-finding trial and an extensive phase three programme were examined with regard to pregnancy, birth and neonatal outcome (Boerrigter et al., 2002) . Data on 340 ongoing pregnancies and 423 infants following ganirelix treatment were compared with 134 pregnancies and 184 infants following GnRH agonist treatment in a long protocol. No significant differences between the two treatment groups were observed in pregnancy and delivery complications or in neonatal characteristics or congenital malformations. To further substantiate the long-term safety of the GnRH antagonist ganirelix with regard to obstetrical and neonatal outcome, the outcome of a cohort of approximately 1000 fetuses (gestational age over 16 weeks) conceived after treatment with ganirelix was prospectively collected and compared with the outcome of a historical control group including 1000 fetuses conceived after treatment with a GnRH agonist long protocol.
Materials and Methods
All data for our study were taken from a large database that is being maintained at Universitair Ziekenhuis (UZ) Brussel, in which all pregnancies resulting from ART treatment in that centre are being followed-up. From mid-2001 to mid-2005 data from 1000 fetuses (gestational age ≥16 weeks) were collected at UZ Brussel from a prospective cohort of women, aged 18-39 years, with an ongoing pregnancy after undergoing COS with recombinant FSH (Puregon w , NV Organon, Oss, The Netherlands) and ganirelix treatment and transfer of fresh IVF or ICSI embryos. Data from 1000 fetuses (gestational age ≥16 weeks) of consecutive pregnant women that underwent COS in a GnRH agonist (buserelin) long protocol between 1996 and 1999, and otherwise met the inclusion criteria (age 18 -39 years and transfer of fresh IVF or ICSI embryos) were used as a historical control group.
This study was reviewed and approved by the Ethics Committee of the hospital. For both cohorts, the standard procedure as applicable at the site was followed. In short, after establishing a vital pregnancy at 6 -7 weeks gestation and a visit to close out the fertility treatment, informed consent was obtained to follow-up the pregnancy and neonate. As the majority of women return to their referring physician for obstetric care, standard forms to document the course of pregnancy, delivery and the immediate post-partum status are sent to the subjects after 6 months pregnancy to be completed by the physician and the subject herself and to be returned to the clinic after birth. Thereafter, a post-partum paediatric examination is scheduled at UZ Brussel within 6 months after birth (Bonduelle et al., 2002) . All demographic data, medical history data and details on ART procedures are reported in an electronic follow-up database specifically developed for this purpose. For this trial, typically the obstetrical history, gestational age, mode of delivery, pregnancy and delivery complications and number of infants with body weight ,2500 g were evaluated for both the ganirelix and historical GnRH agonist groups.
At birth and/or during the follow-up period within 6 months postpartum all congenital malformations were recorded. For the evaluation of congenital malformations, two definitions for major congenital malformations were applied: (i) Definition A: a condition that reduces the viability or compromises the quality of life and requires medical treatment. (ii) Definition B: a condition that causes functional impairment or requires surgical correction. This second definition was also used in a previous IVF/ICSI follow-up study (Bonduelle et al., 2002) .
All remaining congenital malformations were defined as minor congenital malformations and coded following a limited internal checklist. As many minor malformations are only diagnosed after birth and detection depends on the carefulness with which the infant is examined, incidences of minor malformations will only be compared between those subsets of infants that underwent a detailed physical examination during a follow-up visit at our centre. In that way, examination bias is kept to a minimum. The evaluation and classification of the congenital malformations was kept consistent with the working procedure as used for the analysis of the data from the previously published follow-up studies of the Phase two and three development trials (Boerrigter et al., 2002) . In addition, all congenital malformations were coded using the Medical Dictionary for Regulatory Activities (MedDRA; version 9.0) to enable further analysis by organ system. The malformation rates were primarily calculated based on the number of fetuses with gestational age ≥26 weeks (including live borns and stillborns), which is after the period of a late abortion and the lower limit of natural viability.
Statistical analysis
The primary end-point was the incidence of major congenital malformations. With approximately 1000 infants per treatment group and using a 0.05 two-sided significance level, the analysis will have more than 80% power to detect a doubling in the incidence of major malformations between the two groups (i.e. 3 versus 6%).
The incidence of major malformations was analysed by logistic regression, presenting the odds ratio (OR) and corresponding 95% confidence interval (CI) for the comparison between the ganirelix and historical GnRH agonist group. The independent variables in the model are treatment (ganirelix versus GnRH agonist), age of mother, IVF method (ICSI versus non-ICSI) and singleton versus multiple pregnancy.
Results

Evolution of pregnancies and number of infants
The evolution of ongoing pregnancies followed and the number of live born and stillborn infants are presented in Table I . In total, 839 women with ongoing pregnancies were followed in the ganirelix group compared with 753 pregnancies in the historical GnRH agonist group in order to generate data on 1000 fetuses of 16 weeks gestational age in each group. From the pregnancies resulting in live born infants, relatively more multiple pregnancies were reported in the historical GnRH agonist group [233 (31.9%)] compared with 153 (18.7%) in the ganirelix group (P , 0.0001). Of all fetuses followed from 16 weeks gestation onwards 96.9 and 96.3% were live born in the ganirelix and historical GnRH agonist groups, respectively. Most of the fetuses not resulting in live born infants were lost before 26 weeks of gestation, either by selective reduction, induced abortion or spontaneously. In the ganirelix group, 27 fetuses were lost between 16 and 26 weeks gestation and another four stillbirths occurred thereafter. In the historical GnRH agonist group, a total of 37 fetuses were lost: 32 between 16 and 26 weeks gestation and five stillbirths were reported at a later time point.
For 944 infants (94.4%) in the ganirelix cohort, the follow-up was complete, with the majority of these infants (841 infants, 89.1%) being examined by a paediatrician at UZ Brussel. In the historical GnRH agonist group, the follow-up rate was lower (80.6%), and additionally, the number of infants examined at the UZ Brussel was lower (594 infants: 73.7%). Table II shows details on the pregnant mothers and the fertilization method applied. The mean maternal age was comparable between the two groups, viz. 31.7 years in the ganirelix group and 31.4 years in the historical GnRH agonist group and no major differences between the two treatment groups were observed in obstetrical history (gravidity and parity). ICSI was applied most frequently in both groups (68.5% for ganirelix and 66.7% for GnRH agonist) and biopsy sperm was used only in 9.1 and 10.9% of the ganirelix and historical GnRH agonist pregnancies, respectively. There were twice as many women in the ganirelix cohort for whom any medication during pregnancy was reported. Further investigation into the medication used revealed that this mainly reflects an increased reporting on the use of vitamins and folic acid in the ganirelix cohort. The most frequently reported pregnancy complications were premature labour, haemorrhage, vomiting and normal uterine contractions: although of limited clinical relevance, the latter three were more frequently reported in the ganirelix group, both in singleton and in multiple pregnancies.
Maternal characteristics and fertilization method
Delivery data and birth characteristics
Delivery and birth characteristics are presented by singleton and multiple pregnancy in Table III . The majority of singleton pregnancies resulted in spontaneous vaginal deliveries, and this was comparable for both treatment groups (63% for the ganirelix group and 60% for the GnRH agonist cohort). In contrast, the multiple pregnancies mainly resulted in Caesarean section deliveries, but again this was comparable between the ganirelix group (61%) and the historical GnRH agonist cohort (55%). Information on use of concomitant medication missing in 5% and 13% of subjects in the ganirelix and GnRH agonist group, respectively. The pregnancy duration among singletons and twins was comparable in both treatment groups: for singletons 38.9 weeks in both groups and for multiples 35.2 weeks for the ganirelix group and 35.6 weeks for the GnRH agonist group. In line with the gestational age, the frequency of premature births and the frequency of infants with a birthweight below 2500 g or below 1500 g was higher in multiples compared with singletons, but not different between treatment groups, except for the frequency of premature births (gestational age ,37 weeks) which was higher in multiples in the ganirelix group compared with the GnRH agonist group. Table IV presents the incidence of congenital malformations in live born and stillborn fetuses ≥26 weeks gestation. In Supplementary material, Appendix 1 an overview of all reported major malformations (both definitions) is given for all fetuses ≥16 weeks gestation. Overall, 10 infants were live born before 26 weeks of gestational age, but none of them had congenital malformations. Of the 59 fetuses lost between 16 and 26 weeks of gestation a total of six fetuses had at least one major congenital malformation, according to both definitions. In the ganirelix group one fetus was reported to have multiple congenital malformations, which were detected at prenatal screening and for which subsequently a medical termination was performed. In the historical GnRH agonist group trisomy 21, chromosomal abnormality, hydrocephalus, spina bifida and cleft lip bilateralis with cleft palatum was reported in five fetuses. For two fetuses, these events were detected at prenatal screening and both pregnancies were terminated.
Congenital malformations
For 19 infants in the ganirelix cohort (2.0%), a major congenital malformation according to Definition A was reported. When using Definition B, 48 infants (5.0%) were considered to have a major congenital malformation. In the historical GnRH agonist group, 30 fetuses (3.1%) had a major congenital malformation according to Definition A and 52 (5.4%) had a major malformation according to Definition B. Definition A: a condition that reduces the viability or compromises the quality of life and requires medical treatment. Definition B: a condition that causes functional impairment or requires surgical correction. This second definition was also used in a previous IVF/ICSI follow-up study (Bonduelle et al., 2002) . OR, odds ratio; CI, confidence interval.
Statistical analysis of the major congenital malformations in live born and stillborn infants ≥26 weeks is also reflected in Table IV . The OR from the logistic regression was 0.62 (95% CI, 0.34-1.13) using Definition A and 0.94 (95% CI, 0.62 -1.42) when Definition B for classification of major malformations was applied. Thus, the logistic regression analysis indicated no significant differences between the ganirelix and historical GnRH agonist treatment groups in the incidences of major congenital malformations in infants (live born and stillborn) ≥26 weeks gestational age. Unexpectedly, the regression analyses for Definition A further revealed that with increasing maternal age there was a lower chance of major malformations, although analyses using the wider Definition B indicated that none of the independent variables had a significant impact on the outcome.
The total major malformation rate, taking into account all major malformations (Definition B) in fetuses ≥16 weeks gestational age [i.e. including (medical) terminations, stillborns and live borns] was 4.9% in the ganirelix group and 5.7% in the historical GnRH agonist group (OR 0.93; 95% CI, 0.62 -1.40).
Apart from an overall analysis on the incidence of congenital malformations, an additional analysis was performed to investigate the distribution of the events in the different organ systems. Results of this analysis for the major congenital malformations (according to Definition B) are given in Table V . In both treatment groups, the reported major malformations were most frequently categorized as 'gastrointestinal tract disorders congenital' (1.8% for the ganirelix cohort and 1.4% for the historical GnRH agonist cohort), 'cardiac and vascular disorders congenital' (1.0% for the ganirelix cohort and 1.7% for the historical GnRH agonist cohort), 'reproductive tract and breast disorders congenital' (1.1% for the ganirelix cohort and 0.5% for the historical GnRH agonist cohort) and 'musculoskeletal and connective tissue disorders congenital' (0.7% for the ganirelix cohort and 0.9% for the historical GnRH agonist cohort). None of these findings were significantly different.
Overall, the most commonly reported major malformations were 'hernia congenital' (i.e. inguinal hernia; 1.2% for the ganirelix group and 0.9% for the historical GnRH agonist group) and 'cryptorchidism' (0.8% for the ganirelix group and 0.5% for the historical GnRH agonist group). The majority of the infants with inguinal hernia were males (11 in the ganirelix group and 6 in the historical GnRH agonist group). Of the 12 cases of inguinal hernia reported in the ganirelix group, seven were reported in preterm infants, and six of the nine cases in the historical GnRH agonist group were preterm infants. Of the 13 cases of cryptorchidism that were reported overall, nine occurred in fetuses conceived after ICSI fertilization.
In the subset of infants that attended a follow-up examination at UZ Brussel (841 from 
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Large ganirelix pregnancy follow-up trial group), the incidence of infants with at least one minor congenital malformation (and without major malformations), reported either at birth or at follow-up, was similar between the two groups, viz 41.3 and 41.2% in the ganirelix and historical GnRH agonist cohort, respectively. The most frequently reported minor congenital malformations (preferred terms) were haemangioma congenital (11.8% in the ganirelix group versus 9.3% in the historical GnRH agonist group), melanocytic naevus (7.5 versus 4.9%), ear malformation (3.7 versus 5.7%), pilonidal cyst congenital (4.0 versus 4.5%) and skull malformation (4.2 versus 2.4%).
Discussion
In the past, introduction of new fertility techniques and related drugs was done empirically, and no large prospective randomized trials were performed to assure safety of a new fertility technique or drug before putting it into routine practice. While for the recombinant fertility products much larger trials were performed to establish safety and efficacy for women undergoing COS for IVF embryo transfer, there is limited information available that documents safety for the offspring (Out et al., 1999; European Recombinant hCG group, 2000) . This is probably best explained by the high similarity of recombinant products with endogenously circulating gonadotrophins, meaning that no teratogenic effect as such is to be expected. For GnRH agonists, prospective data on neonatal outcome of the offspring is lacking, which is intriguing in view of the fact that accidental exposure in early pregnancies cannot be completely ruled out when the GnRH agonist protocol is started in the luteal phase. Nevertheless, data from a large review on accidental exposures in pregnancy are reassuring (Platteau et al., 2000) . For GnRH antagonists safety and efficacy of the compounds in infertility patients was established in a well-controlled setting. In addition, the pregnancy and offspring resulting from the IVF-embryo transfer treatment were also prospectively followed up for the two marketed GnRH antagonists cetrorelix (Ludwig et al., 2001) and ganirelix (Boerrigter et al., 2002) . As much larger series are needed to judge whether GnRH antagonists may be linked to an increased risk of major congenital malformations, the current trial including 1000 fetuses per group was performed, and reveals a comparable neonatal outcome and major malformation rate to fetuses after GnRH agonist treatment.
To guarantee that prospective data were collected in a consistent manner, all data were acquired in a single centre. In that way, detection of malformations, which is known to vary considerably among countries and examiners, could be standardized to a large extent. The weakness of a single-centre approach, however, is that a randomized design cannot be applied, as, even in a very large practice, it would take many years to reach the required numbers. Instead, a historical GnRH agonist cohort was included as control, for which data were prospectively collected from 1996 to 1999, although data from the prospective ganirelix group were obtained more recently (from 2001 to 2005), which could have influenced the results to some extent.
The current analysis reveals that when a strict definition is applied (Definition A) the incidence of major malformations after COS treatment combined with the GnRH antagonist ganirelix is comparable to that observed in the historical GnRH agonist cohort (OR from the logistic regression 0.62; 95% CI, 0.34 -1.13). Unexpectedly, the logistic regression showed that age was a significant positive co-variable, implying that with increasing age of the mother there would be a smaller chance of having a child with a major congenital malformation. A possible explanation would be that with increasing age of the mother more ultrasound and invasive prenatal diagnosis is performed, leading to a higher rate of pregnancy termination. This phenomenon could be more common in the recently treated group with ganirelix. However, as there was only one pregnancy termination for malformations (between 16 and 25 weeks) in the ganirelix group this is unlikely to have affected the outcome and therefore the finding is considered to be related to statistical variation.
When another widely used, less strict definition was applied (Definition B), the absolute major malformation rate was higher (5.0% in the ganirelix group and 5.4% in the historical GnRH agonist cohort), and again the OR revealed no significant difference with the historical GnRH agonist cohort (OR 0.94; 95% CI, 0.62-1.42). Using Definition B none of the investigated co-variables (age, singleton/multiple, IVF/ ICSI) had a significant effect. This is in line with previous publications and meta-analyses on malformation rate in ICSI versus IVF, where no significant differences were found (Bonduelle et al., 2002; Lie et al., 2005) .
General investigation of the overall reported major malformations revealed that incidences of the two most frequently reported major malformations according to Definition B are congenital inguinal hernia and cryptorchidism. Inguinal hernia is related to the high number of multiples, where the prematurity rate is higher, and consequently, the chance is higher that the inguinal canal is not closed at birth. Therefore, it should be noted that some registers do not report inguinal hernias as malformations in premature infants born at or before ,36 weeks of gestation. The incidence of cryptorchidism is in line with reported frequencies in IVF and ICSI and probably related to different maternal and paternal risk factors (Pierik et al., 2004) . The number of infants with neural tube defects is numerically lower in the ganirelix group, which could be related to the higher percentage of subjects taking vitamins and folic acid in that group. However, with the limited number of cases the difference is not statistically significant and thus the relatively more common intake of vitamins and folic acid in the ganirelix group is unlikely to have had an impact on the overall comparison.
The results obtained in this large ganirelix group, are well in line with those previously published by Boerrigter et al. (2002) . When applying the same definition, their reported major malformation rates were somewhat lower (3.8% for the ganirelix group and 3.3% for the GnRH agonist group), which may be explained by the smaller sample size and the lower number of infant follow-up visits that may lead to the detection of additional malformations. Combining the information would lead to an overall incidence of major malformations (Definition B) of 4.6% in the ganirelix group and 5.1% in the GnRH agonist group. Both incidences are in line with currently reported rates (Hansen et al., 2005) although it must be noted that incidences reported in registries are still variable, mainly as a result of a lack of uniformity in many aspects, such as different criteria used for congenital malformations, different cut-off points of gestational age and difference in inclusion or exclusion of stillbirths.
The minor malformation rates of 40% as reported in this analysis are considered to be maximum estimates, since the analysed subsets consisted of infants for whom a follow-up visit was completed. As many of the minor malformations are only detected in the first weeks after birth, this means that in this group, the likelihood of detecting a minor malformation is highest. Moreover, these infants were all examined at UZ Brussel by a clinical geneticist or paediatrician trained to detect minor malformations, including those of limited clinical relevance. In that respect it is reassuring that even in this large data set (594 infants in the GnRH agonist cohort and 841 infants in the ganirelix cohort) no differences in minor malformations are detected between the two treatments.
The current trial also shows the impact the change in the Belgian legislation, which limits the number of embryos transferred in young women (,36 years) to a single embryo, has had. As there was a large time difference between the two cohorts, the twinning rate was lower in the more recently recruited ganirelix cohort. In the current trial, multiple pregnancy was not a significant factor in the analysis for major malformations. This seems to be in contrast with registry data and the results published in 2002 (Bonduelle et al., 2002) where a significantly higher malformation rate was reported in the multiple pregnancies. Although the difference is not substantial, it became significant owing to the large sample size that was studied (almost 6000 infants, of which 3000 originated from multiple pregnancies). However, it should be noted that the data from this trial confirm that gestational age and birthweight of neonates resulting from a multiple pregnancy are lower compared with the singletons, for which significant health consequences and impact on health care costs have been documented (Chambers et al., 2007) .
To the best of our knowledge, this report presents the largest, prospective, pregnancy follow-up trial ever performed for any fertility drug. It reveals that in terms of neonatal outcome and risk of major malformations, treatment with the GnRH antagonist ganirelix during COS is as safe as traditional GnRH agonists.
